AU2020413284A1 - Aliphatic acid amide derivative - Google Patents

Aliphatic acid amide derivative Download PDF

Info

Publication number
AU2020413284A1
AU2020413284A1 AU2020413284A AU2020413284A AU2020413284A1 AU 2020413284 A1 AU2020413284 A1 AU 2020413284A1 AU 2020413284 A AU2020413284 A AU 2020413284A AU 2020413284 A AU2020413284 A AU 2020413284A AU 2020413284 A1 AU2020413284 A1 AU 2020413284A1
Authority
AU
Australia
Prior art keywords
drug
compound
alkyl
treating
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020413284A
Other languages
English (en)
Inventor
Yoshinori AIHARA
Andrew Simon Bell
Jeremy Besnard
Yuki Fujii
Masayuki SAKUMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2020413284A1 publication Critical patent/AU2020413284A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020413284A 2019-12-24 2020-12-23 Aliphatic acid amide derivative Pending AU2020413284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-232927 2019-12-24
JP2019232927 2019-12-24
PCT/JP2020/048117 WO2021132311A1 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Publications (1)

Publication Number Publication Date
AU2020413284A1 true AU2020413284A1 (en) 2022-08-18

Family

ID=76574184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020413284A Pending AU2020413284A1 (en) 2019-12-24 2020-12-23 Aliphatic acid amide derivative

Country Status (14)

Country Link
US (3) US12503463B2 (https=)
EP (1) EP4082616B1 (https=)
JP (1) JP7662534B2 (https=)
KR (1) KR20220120625A (https=)
CN (1) CN114981264B (https=)
AU (1) AU2020413284A1 (https=)
BR (1) BR112022011844A2 (https=)
CA (1) CA3161806A1 (https=)
ES (1) ES3040677T3 (https=)
HU (1) HUE072877T2 (https=)
MX (1) MX2022007947A (https=)
PL (1) PL4082616T3 (https=)
PT (1) PT4082616T (https=)
WO (1) WO2021132311A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880930A (en) 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
EP0732332B1 (en) 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンd3受容体リガンドとしてのその使用
FR2827287B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2006508101A (ja) 2002-11-08 2006-03-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー フェニルアルキルおよびピリジルアルキルピペラジン誘導体
AU2006239302B2 (en) 2005-04-26 2011-07-07 Hypnion, Inc. Benzisoxazole piperazine compounds and methods of use thereof
PL392436A1 (pl) 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
WO2014079155A1 (zh) * 2012-11-26 2014-05-30 辽宁贝雷生物制药有限公司 苯并五元氮杂环基哌嗪或哌啶衍生物的用途
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체

Also Published As

Publication number Publication date
US12503463B2 (en) 2025-12-23
TW202136235A (zh) 2021-10-01
KR20220120625A (ko) 2022-08-30
CA3161806A1 (en) 2021-07-01
EP4082616A1 (en) 2022-11-02
US20220073506A1 (en) 2022-03-10
US20260078115A1 (en) 2026-03-19
JPWO2021132311A1 (https=) 2021-07-01
BR112022011844A2 (pt) 2022-08-30
WO2021132311A1 (ja) 2021-07-01
EP4082616B1 (en) 2025-09-03
US11339151B2 (en) 2022-05-24
JP7662534B2 (ja) 2025-04-15
CN114981264A (zh) 2022-08-30
PL4082616T3 (pl) 2025-12-15
MX2022007947A (es) 2022-07-27
EP4082616A4 (en) 2024-01-03
US20220213079A1 (en) 2022-07-07
PT4082616T (pt) 2025-12-02
HUE072877T2 (hu) 2025-12-28
CN114981264B (zh) 2024-07-26
ES3040677T3 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
US20260078115A1 (en) Aliphatic acid amide derivative
CA2931732A1 (en) Substituted benzamides and methods of use thereof
CA3111649A1 (en) Tricyclic compounds acting on crbn proteins
CA2878006C (en) Carbamate/urea derivatives
US20230399308A1 (en) 2,6-disubstituted pyridine derivative
CA2999769A1 (en) Therapeutic compounds and methods of use thereof
JP2020023570A6 (ja) 2,6−ジ置換ピリジン誘導体
JP7655885B2 (ja) 脂肪族酸アミド誘導体を含有する医薬組成物
TWI917344B (zh) 脂肪族酸醯胺衍生物
KR100700422B1 (ko) 아데노신 수용체 리간드로서의7-([1,4]다이옥산-2-일)-벤조티아졸 유도체
HK40079616B (en) Aliphatic acid amide derivative
EA046822B1 (ru) Производное амида алифатической кислоты
HK40079616A (en) Aliphatic acid amide derivative
US20250163062A1 (en) Wnt pathway inhibitor compounds
CA3199269A1 (en) Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2024022365A1 (zh) 一种Wnt通路抑制剂化合物
CN121717808A (zh) 咪唑并吡啶类衍生物及其制备方法、药物组合物和应用
HK40017726A (en) 2,6-disubstituted pyridine derivative